Search Results - castrate+resistant

1 Results

Sort By:

Treatment of Prostate Cancer Using Anti-androgen Small Molecules

Abstract: Castrate-resistant prostate cancer (CRPC) is characterized by androgen-independent cancer cells that have adapted to the depletion of hormones and continue to grow. Abnormal androgen receptor signaling is known to drive advanced castrate-resistant prostate cancer. The small molecule compounds of this invention are antiandrogens that target...

Published: 4/8/2024 | Inventor(s): Jane Trepel Neckers, Yeong Kim, Sunmin Lee, Vineet Kumar, Sanjay Malhotra

Keywords(s): Antiandrogen, castrate resistant, CRPC, PROSTATE CANCER, small molecule, steroid hormone receptor.

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology